Holen Sie sich die Stockscreener-App
49.83
5.71%
-3.015
Handel nachbörslich:
55.05
5.22
+10.48%
Schlusskurs vom Vortag:
$52.84
Offen:
$50.445
24-Stunden-Volumen:
9.03M
Relative Volume:
0.80
Marktkapitalisierung:
$19.68B
Einnahmen:
$3.14B
Nettoeinkommen (Verlust:
$-3.36B
KGV:
-5.7079
EPS:
-8.73
Netto-Cashflow:
$-4.03B
1W Leistung:
-1.37%
1M Leistung:
+18.08%
6M Leistung:
+107.19%
1J Leistung:
+64.62%
1-Tages-Spanne:
$48.09
$51.86
1-Wochen-Bereich:
$48.09
$54.94
52-Wochen-Spanne:
$22.28
$55.20
Moderna Inc Stock (MRNA) Company Profile
Firmenname
Moderna Inc
Sektor
Branche
Telefon
(617) 714-6500
Adresse
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
49.83 | 20.87B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.27 | 123.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.66 | 83.60B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
748.72 | 46.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.65 | 43.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.04 | 34.79B | 4.98B | 69.60M | 525.67M | 0.5198 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Equal Weight |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-12 | Eingeleitet | Jefferies | Hold |
| 2025-03-13 | Eingeleitet | Citigroup | Neutral |
| 2025-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Herabstufung | Goldman | Buy → Neutral |
| 2024-12-18 | Herabstufung | Argus | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-19 | Eingeleitet | Berenberg | Hold |
| 2024-11-18 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-09-13 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Herabstufung | Jefferies | Buy → Hold |
| 2024-09-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-11-03 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-06-26 | Hochstufung | UBS | Neutral → Buy |
| 2023-04-26 | Eingeleitet | Guggenheim | Neutral |
| 2023-03-13 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-02-24 | Herabstufung | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Hochstufung | Jefferies | Hold → Buy |
| 2022-12-14 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2022-01-26 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Eingeleitet | UBS | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Sell |
| 2021-10-15 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Bestätigt | Jefferies | Hold |
| 2021-02-01 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Herabstufung | Needham | Buy → Hold |
| 2020-11-23 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-11-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-07-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Eingeleitet | Jefferies | Buy |
| 2020-06-30 | Eingeleitet | Argus | Buy |
| 2020-06-08 | Eingeleitet | Barclays | Overweight |
| 2020-04-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-05 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Moderna Inc Aktie (MRNA) Neueste Nachrichten
Analysts Are Bullish on These Healthcare Stocks: Nyxoah (NYXH), Moderna (MRNA) - The Globe and Mail
Should You Listen to Billionaires to Buy Moderna Stock in 2026? - TradingKey
Moderna, Inc. (MRNA) Stock Analysis: Navigating Challenges with a Diverse Vaccine Pipeline - DirectorsTalk Interviews
Moderna’s dual Covid-flu vaccine poised for EMA approval on positive CHMP take - Yahoo Finance
Why Moderna Inc (MRNA) May Struggle to Outperform: A Look at Fut - GuruFocus
MRNA Stock Gains After CHMP Endorses COVID-19-Influenza Combo Shot - Zacks Investment Research
Moderna Stock (MRNA) Opinions on Piper Sandler Price Target Hike - Quiver Quantitative
Moderna, Inc. $MRNA Shares Purchased by Banco Santander S.A. - MarketBeat
Moderna’s EU Backing For Combo Vaccine Shifts Respiratory Growth Focus - Yahoo Finance
Moderna Inc (MRNA) Stock Price, Trades & News - GuruFocus
European health agency recommends approving Moderna’s combined flu, COVID vaccine - The Hill
This Is What Whales Are Betting On Moderna - Benzinga
Europe just approved a combined flu and COVID shot. Why hasn’t the US? - Fast Company
Moderna’s combination flu, COVID shot wins over European drug regulators - BioPharma Dive
Rothschild & Co Redburn Adjusts Price Target on Moderna to $40 From $36, Maintains Neutral Rating - marketscreener.com
Uncertainty Looms Over Pharma’s Legal Strategy as States Challenge New Vaccine Schedule - BioSpace
Moderna (MRNA) Gains EMA Recommendation for Combo Vaccine - GuruFocus
Why Is Moderna Stock Moving Today? Europe Clears Moderna’s Dual Vaccine - Tokenist
EU regulator backs approval for Moderna’s combined COVID, flu shot - WTVB
EU regulator backs approval for Moderna's combined COVID and flu vaccine - marketscreener.com
Moderna Gets EU Approval for mRNA Combination Covid-Flu Shot - Bloomberg.com
Moderna’s flu-COVID combo vaccine gets EU regulatory backing By Investing.com - Investing.com India
Moderna Says It Received Positive EU Panel Opinion for Flu-COVID Combination Vaccine - marketscreener.com
Moderna (MRNA) Gains Positive Opinion for Combo Vaccine in EU - GuruFocus
Moderna (MRNA) Nears EU Approval for Combined Flu and COVID-19 V - GuruFocus
Moderna’s Covid-Flu Vaccine Recommended for Approval in EU - WSJ
Moderna gets EU approval for mRNA combination Covid-flu shot - Moneycontrol.com
Moderna’s flu-COVID combo vaccine gets EU regulatory backing - Investing.com
European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19 - ACCESS Newswire
World’s first flu-COVID combo shot wins key EU backing for over-50s - Stock Titan
Moderna Wins European Medicines Agency's Positive Opinion for Combined COVID-19, Influenza Vaccine - marketscreener.com
Ema recommends granting marketing authorisation in EU for mCombriax - marketscreener.com
Moderna (MRNA) Is Up 10.2% After FDA Accepts Full Review Of Its mRNA Flu Vaccine - simplywall.st
Analyst recommendations: Spotify, Gartner, Godaddy, Medline, Moderna… - marketscreener.com
Moderna (MRNA) Stock Review: Performance & Valuation Concerns in 2026News and Statistics - IndexBox
Moderna president Hoge sells $7.8m in MRNA stock - Investing.com South Africa
Moderna president Hoge sells $7.8m in MRNA stock By Investing.com - Investing.com Canada
Stephen Hoge Sells 160,009 Shares of Moderna (NASDAQ:MRNA) Stock - MarketBeat
[Form 4] Moderna, Inc. Insider Trading Activity - Stock Titan
Moderna Royalty Loss Raises Covid-Shot Trial Stakes (Correct) - Bloomberg Law News
Moderna's Damages Expert Limited In March Patent Trial - Law360
Moderna's Ups and Downs: Here's What You Need to Know Before Investing. - Nasdaq
Moderna's Ups and Downs: Here's What You Need to Know Before Investing. - The Motley Fool
3 Reasons to Avoid MRNA and 1 Stock to Buy Instead - Finviz
A Fresh Look At Moderna (MRNA) Valuation After A Sharp Share Price Rebound - Yahoo Finance
MRNA Stock Surges 26% With A 7-day Winning Spree On FDA Flu Vaccine Review - Trefis
How To Read FDA's Flip-Flop On Moderna Flu Vaccine - Law360
What the Options Market Tells Us About ModernaModerna (NASDAQ:MRNA) - Benzinga
Moderna says FDA will consider its new flu shot after resolving public dispute - Devils Lake Journal
Moderna Stock: How Far Can The Flu Shot Fly? - Forbes
FDA Moderna review sets up pivotal test for mRNA flu jabs - The Pharma Letter
Finanzdaten der Moderna Inc-Aktie (MRNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.89%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):